Anti-Bv8 Antibody and Metronomic Gemcitabine Improve Pancreatic Adenocarcinoma Treatment Outcome Following Weekly Gemcitabine Therapy

This publication has 41 references indexed in Scilit:

• Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models
  Gut, 2012
• VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunity–Induced Tumor Regression
  Cancer Research, 2012
• Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
  Molecular Cancer Therapeutics, 2012
• Host Response to Short-term, Single-Agent Chemotherapy Induces Matrix Metalloproteinase-9 Expression and Accelerates Metastasis in Mice
  Cancer Research, 2011
• Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
  British Journal of Cancer, 2010
• Increase in frequency of myeloid‐derived suppressor cells in mice with spontaneous pancreatic carcinoma
  Immunology, 2009
• Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents
  Cancer Cell, 2008
• Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression
  Proceedings of the National Academy of Sciences, 2008
• Tumour stem cells and drug resistance
  Nature Reviews Cancer, 2005
• The anti-angiogenic basis of metronomic chemotherapy
  Nature Reviews Cancer, 2004